I know nothing of this company. But either way, looks like a nice example of buying something beaten up down 99% after it starts rallying.
When it goes down usually it goes down pretty fast (crypto won't be an exception btw), important not to overstay your welcome.
I do not use this strategy at all. Adding an example, learning a bit more every few month or so......
MNKD is on a slow bullish trend.
weekly, daily, and hourly bullish trend
may retrace to support at $1.18 based on daily RSI, but will likely continue to rise
support/entry: $1.18
target: is $2.20
stop $1.10
the 200 day ema has cut thru the Bollinger bands, and for some reason, price seems to spike after this action. Price is closing in on the 200 day ema which should push this stock into bullish mode. Wedge patter is close to completion.
Looking for a resistance level that causes a reversal of trend. You can see the 2.01 resistance level was hit on 9/6, and 9/7 the price fell through to 1.78. If the downward trend continues, the next resistance level to be hit would be 1.5. Substantial sell volume on 9/5, 9/6 and 9/7 could be indicative of a higher likelihood for a trend reversal early next...
MNKD had a volume surge on Friday after some positive results were shown.
ADX is still flat which is currently over 10 +DMI is over 17 and -DMI is over 16. It closed over the 50 day moving average which is currently at 1.8.
Entry would be 1.75/1.81/1.87/1.91
Pivot is 1.97
Resistance is 2.03/2.07/2.013/2.23
For me I would look to enter this from 1.81 to 1.87...
Technically speacking it is getting squeezed in a wedge. The move could be up since last earning were not half bad, they were actually pretty good, I am surprized that the move hasn't happened yet.
MNKD looks like a nice wedge set up. Looking at buy points at the red and blue lines, allowing me to average down. A break out from this trend should carry this stock upwards. Worth keeping on a watch list.
This is why you buy/sell only at the beginning/end of the session.
Especially in a downtrend/uptrend a buy/sell opportunity is valid only at the end....
MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a portable inhaler. AFREZZA utilizes its Technosphere formulation technology. Technosphere is a drug delivery platform that may allow the oral inhalation of a range of therapeutics. Technosphere powders are based on the Company's fumaryl diketopiperazine (FDKP), which is a potential of Hydrogen (pH)-sensitive organic molecule that self-assembles into small particles under acidic conditions. The Company has also created a range of breath-powered, dry powder inhalers. Its inhalers can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format.
This website uses cookies to ensure you get the best experience on our website. To learn more about cookies, including how to control cookies, please read our Cookies Policy.
MNKD
